ImageneBio (IMA) Competitors $14.67 -0.03 (-0.20%) As of 08/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMA vs. ALVO, IMVT, MOR, KYMR, CRNX, RARE, GMTX, OGN, CPRX, and NAMSShould you be buying ImageneBio stock or one of its competitors? The main competitors of ImageneBio include Alvotech (ALVO), Immunovant (IMVT), MorphoSys (MOR), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), Gemini Therapeutics (GMTX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. ImageneBio vs. Its Competitors Alvotech Immunovant MorphoSys Kymera Therapeutics Crinetics Pharmaceuticals Ultragenyx Pharmaceutical Gemini Therapeutics Organon & Co. Catalyst Pharmaceuticals NewAmsterdam Pharma Alvotech (NASDAQ:ALVO) and ImageneBio (NASDAQ:IMA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership. Which has more risk & volatility, ALVO or IMA? Alvotech has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Do analysts prefer ALVO or IMA? Alvotech presently has a consensus target price of $14.00, suggesting a potential upside of 65.48%. ImageneBio has a consensus target price of $35.50, suggesting a potential upside of 141.99%. Given ImageneBio's higher possible upside, analysts clearly believe ImageneBio is more favorable than Alvotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alvotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ImageneBio 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better earnings and valuation, ALVO or IMA? ImageneBio has lower revenue, but higher earnings than Alvotech. ImageneBio is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlvotech$491.98M5.18-$231.86M$0.3722.86ImageneBio$9.16M6.44-$49.23M-$7.68-1.91 Does the media favor ALVO or IMA? In the previous week, ImageneBio had 2 more articles in the media than Alvotech. MarketBeat recorded 6 mentions for ImageneBio and 4 mentions for Alvotech. ImageneBio's average media sentiment score of 1.08 beat Alvotech's score of 0.00 indicating that ImageneBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImageneBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of ALVO or IMA? 75.0% of ImageneBio shares are held by institutional investors. 0.5% of Alvotech shares are held by company insiders. Comparatively, 5.9% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ALVO or IMA more profitable? Alvotech has a net margin of 16.42% compared to ImageneBio's net margin of 0.00%. ImageneBio's return on equity of -23.94% beat Alvotech's return on equity.Company Net Margins Return on Equity Return on Assets Alvotech16.42% -36.37% 12.70% ImageneBio N/A -23.94%-21.62% SummaryImageneBio beats Alvotech on 9 of the 15 factors compared between the two stocks. Get ImageneBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMA vs. The Competition Export to ExcelMetricImageneBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.97M$2.99B$5.52B$9.72BDividend YieldN/A2.42%4.60%4.12%P/E Ratio-1.9117.2130.0124.75Price / Sales6.44314.00450.9398.56Price / CashN/A41.7736.7758.47Price / Book0.517.318.185.59Net Income-$49.23M-$54.43M$3.26B$265.99M7 Day Performance-15.10%0.01%6.13%5.06%1 Month Performance-12.05%0.63%0.07%0.61%1 Year Performance-24.77%8.41%36.31%22.82% ImageneBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMAImageneBio3.4677 of 5 stars$14.67-0.2%$35.50+142.0%-24.8%$58.97M$9.16M-1.9170Positive NewsUpcoming EarningsALVOAlvotech2.8337 of 5 stars$9.71-1.1%$14.00+44.3%-22.5%$2.93B$491.98M26.281,032IMVTImmunovant1.5224 of 5 stars$16.72-0.2%$36.40+117.7%-47.1%$2.86BN/A-6.10120MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics3.3468 of 5 stars$43.50-1.6%$59.11+35.9%-2.0%$2.83B$58.89M-14.03170Positive NewsCRNXCrinetics Pharmaceuticals3.3631 of 5 stars$29.58-2.4%$69.50+134.9%-43.6%$2.77B$760K-7.74210News CoverageEarnings ReportRAREUltragenyx Pharmaceutical4.3852 of 5 stars$27.83+0.8%$82.57+196.8%-45.0%$2.63B$560.23M-4.731,294Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionGMTXGemini TherapeuticsN/A$60.61+0.0%N/A+34.7%$2.63BN/A-60.6130OGNOrganon & Co.4.7542 of 5 stars$9.98+0.1%$18.00+80.5%-54.2%$2.59B$6.29B3.464,000Earnings ReportDividend AnnouncementCPRXCatalyst Pharmaceuticals4.8837 of 5 stars$21.13+1.6%$32.83+55.4%+7.5%$2.58B$491.73M13.4680Analyst DowngradeNAMSNewAmsterdam Pharma3.5769 of 5 stars$22.98-1.9%$41.30+79.8%+45.5%$2.58B$45.56M-12.204News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies ALVO Competitors IMVT Competitors MOR Competitors KYMR Competitors CRNX Competitors RARE Competitors GMTX Competitors OGN Competitors CPRX Competitors NAMS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMA) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImageneBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImageneBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
